MedTrace Logo

OLE of Phase 2b/3 Study ANAVEX2-73-AD-004

NCT04314934 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-08-12

No results posted yet for this study

Summary

This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.

Conditions

  • Alzheimer Disease

Interventions

DRUG

ANAVEX2-73

Oral capsules

Sponsors & Collaborators

  • Anavex Australia Pty Ltd.

    collaborator INDUSTRY

  • Anavex Germany GmbH

    collaborator INDUSTRY

  • Anavex Life Sciences Corp.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-10
Primary Completion
2024-06-14
Completion
2024-06-14

Countries

  • Australia
  • Canada
  • Germany
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04314934 on ClinicalTrials.gov